Patents by Inventor John Thomas Norton

John Thomas Norton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20190389964
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 26, 2019
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • Humanized antibodies that bind LGR5
    Patent number: 10358500
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 23, 2019
    Assignee: BIONOMICS INC.
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20170114145
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 27, 2017
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • Humanized antibodies that bind LGR5
    Patent number: 9546214
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: January 17, 2017
    Assignee: Bionomics, Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20160031984
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 4, 2016
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton